MA20150232A1 - Protéines de fusion de l'interleukine-10 et leurs utilisations - Google Patents
Protéines de fusion de l'interleukine-10 et leurs utilisationsInfo
- Publication number
- MA20150232A1 MA20150232A1 MA37793A MA37793A MA20150232A1 MA 20150232 A1 MA20150232 A1 MA 20150232A1 MA 37793 A MA37793 A MA 37793A MA 37793 A MA37793 A MA 37793A MA 20150232 A1 MA20150232 A1 MA 20150232A1
- Authority
- MA
- Morocco
- Prior art keywords
- interleukin
- fusion
- proteins
- fusion proteins
- methods
- Prior art date
Links
- 102000003814 Interleukin-10 Human genes 0.000 title abstract 2
- 108090000174 Interleukin-10 Proteins 0.000 title abstract 2
- 229940076144 interleukin-10 Drugs 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La présente invention concerne en général des protéines de fusion d'anticorps et d'interleukine-10 (il-10). De plus, la présente invention concerne des polynucléotides codant pour de telles protéines de fusion, et des vecteurs et cellules hôtes comprenant de tels polynucléotides. L'invention concerne en outre des procédés de production des protéines de fusion de l'invention et des procédés d'utilisation de celles-ci dans le traitement d'une maladie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12179709 | 2012-08-08 | ||
PCT/EP2013/066342 WO2014023673A1 (fr) | 2012-08-08 | 2013-08-05 | Protéines de fusion de l'interleukine-10 et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
MA20150232A1 true MA20150232A1 (fr) | 2015-07-31 |
Family
ID=48917543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37793A MA20150232A1 (fr) | 2012-08-08 | 2013-08-05 | Protéines de fusion de l'interleukine-10 et leurs utilisations |
Country Status (23)
Country | Link |
---|---|
US (2) | US9346872B2 (fr) |
EP (1) | EP2882774B1 (fr) |
JP (3) | JP2015530983A (fr) |
KR (1) | KR20150038012A (fr) |
CN (1) | CN104540848B (fr) |
AR (1) | AR092050A1 (fr) |
AU (1) | AU2013301656A1 (fr) |
BR (1) | BR112015002085A2 (fr) |
CA (1) | CA2876285A1 (fr) |
CL (1) | CL2014003605A1 (fr) |
CO (1) | CO7151522A2 (fr) |
CR (1) | CR20140565A (fr) |
EA (1) | EA201500208A1 (fr) |
HK (1) | HK1209439A1 (fr) |
IL (1) | IL236809A0 (fr) |
MA (1) | MA20150232A1 (fr) |
MX (1) | MX2015001675A (fr) |
PE (1) | PE20150645A1 (fr) |
PH (1) | PH12015500284A1 (fr) |
SG (1) | SG11201408526SA (fr) |
TW (1) | TW201418283A (fr) |
WO (1) | WO2014023673A1 (fr) |
ZA (1) | ZA201409304B (fr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG187746A1 (en) | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
PE20140303A1 (es) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | Polipeptidos interleuquina-2 mutantes |
WO2013148117A1 (fr) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques |
EP2950807B1 (fr) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Compositions et procédés à utiliser pour le traitement de troubles métaboliques |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
JP2016535770A (ja) | 2013-11-01 | 2016-11-17 | スフェリウム バイオメッド エス.エル. | 治療用及び美容用物質を経皮送達するための封入体 |
RU2016135788A (ru) * | 2014-02-06 | 2018-03-07 | Ф.Хоффманн-Ля Рош Аг | Иммуноконъюгаты интерлейкина 10 |
US10993990B2 (en) * | 2014-05-16 | 2021-05-04 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
KR20170065026A (ko) | 2014-07-30 | 2017-06-12 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애 치료용으로 이용되는 조성물 및 방법 |
CA2961587A1 (fr) | 2014-10-31 | 2016-05-06 | Ngm Biopharmaceuticals, Inc. | Compositions et leurs methodes d'utilisation pour le traitement de troubles metaboliques |
EP3224275B1 (fr) | 2014-11-14 | 2020-03-04 | F.Hoffmann-La Roche Ag | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |
AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
WO2016156291A1 (fr) | 2015-03-31 | 2016-10-06 | F. Hoffmann-La Roche Ag | Molécules de liaison à l'antigène comprenant un ligand trimérique des membres de la famille du tnf |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
BR112018002570A2 (pt) | 2015-10-02 | 2018-10-16 | Hoffmann La Roche | molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo |
US11219645B2 (en) | 2015-11-18 | 2022-01-11 | Duke University | Tumor infiltrating lymphocytes for treatment of cancer |
CA3006477A1 (fr) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions a greffe de cytokine-anticorps et procedes d'utilisation pour l'immunoregulation |
CN106349393B (zh) * | 2015-12-21 | 2020-10-30 | 合肥立方制药股份有限公司 | 一种增强抗体药物稳定性的结构 |
TWI815793B (zh) | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | 結合蛋白質及其使用方法 |
JP7084881B2 (ja) | 2016-06-22 | 2022-06-15 | アルカームス インコーポレーテッド | Il-10の免疫刺激特性および抗炎症特性を調節するための組成物および方法 |
CN108948207B (zh) * | 2017-05-22 | 2020-11-13 | 杭州博虎生物科技有限公司 | 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
US20200277350A1 (en) * | 2017-09-25 | 2020-09-03 | Dingfu Biotarget Co., Ltd. | Proteinaceous heterodimer and use thereof |
CN111132998B (zh) * | 2017-09-25 | 2024-01-30 | 苏州丁孚靶点生物技术有限公司 | 用于癌症治疗的方法和组合物 |
US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
AU2019328575A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
JP7397874B2 (ja) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
WO2020108426A1 (fr) * | 2018-11-26 | 2020-06-04 | 江苏恒瑞医药股份有限公司 | Variant d'interleukine 10 humaine et dérivé correspondant |
US11084857B2 (en) | 2018-12-05 | 2021-08-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Nsp-interleukin-10 proteins and uses thereof |
WO2020160244A1 (fr) * | 2019-02-01 | 2020-08-06 | Uab Research Foundation | Procédés et compositions pour antagonisme de la signalisation induite par l'il10 |
US10858412B2 (en) | 2019-03-06 | 2020-12-08 | Deka Biosciences, Inc. | Antibody variable domain regions fused to IL-10 variant molecules |
CN111909276A (zh) * | 2019-05-10 | 2020-11-10 | 复旦大学 | 一种融合蛋白及其用途 |
KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
US20220259278A1 (en) * | 2019-07-08 | 2022-08-18 | Progen Co., Ltd. | Novel fusion protein and use of same |
WO2021006603A1 (fr) * | 2019-07-08 | 2021-01-14 | 주식회사 프로젠 | Nouvelle composition pharmaceutique pour le traitement de maladies allergiques |
CN114302891A (zh) * | 2019-07-08 | 2022-04-08 | 普罗根有限公司 | 新的il-10变体蛋白及其用途 |
CN112618698B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白的注射制剂 |
CN112625137B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白及其医药用途 |
IL295077A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Methods for treating age-related and inflammatory diseases |
IL295083A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Methods for activating regulatory t cells |
IL295084A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Chromatography resin and its uses |
CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
US11673930B2 (en) | 2020-05-12 | 2023-06-13 | Regeneran Pharmaceuticals, Inc. | IL10 agonists and methods of use thereof |
WO2021230705A1 (fr) * | 2020-05-14 | 2021-11-18 | 주식회사 프로젠 | Nouvelle protéine de fusion recombinante et utilisation associée |
JP2023527869A (ja) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
WO2021247003A1 (fr) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Méthodes de traitement de troubles liés au vieillissement |
EP4181957A1 (fr) | 2020-07-20 | 2023-05-24 | Deka Biosciences, Inc. | Protéine de fusion à deux cytokines comprenant de l'il-10 |
TW202216744A (zh) * | 2020-07-20 | 2022-05-01 | 美商維埃拉生物股份有限公司 | 用於治療自體免疫性病症和炎性病症之免疫細胞介素 |
US20240034764A1 (en) * | 2020-12-10 | 2024-02-01 | Joint Stock Company "Biocad" | Immunocytokine for activating human il-10ra receptor and use thereof |
KR20220099656A (ko) * | 2021-01-07 | 2022-07-14 | 주식회사 프로젠 | 신규 il-10 변이체 융합단백질 생산용 세포주 및 그의 용도 |
WO2022165443A1 (fr) * | 2021-02-01 | 2022-08-04 | AskGene Pharma, Inc. | Molécules chimériques comprenant un polypeptide agoniste de l'il-10 ou du tgf-bêta |
WO2023078245A1 (fr) * | 2021-11-02 | 2023-05-11 | 广东菲鹏制药股份有限公司 | Protéine de fusion monomère d'il-10 et son utilisation |
WO2023168363A1 (fr) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Méthode de traitement du cancer du pancréas |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2388385B1 (fr) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
CA2885854C (fr) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anticorps anti-p-selectine |
EP1919950A1 (fr) * | 2004-07-15 | 2008-05-14 | Xencor, Inc. | Variantes genetiques de fc optimisees |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
BRPI0709787A2 (pt) | 2006-05-08 | 2011-03-29 | Philogen Spa | citocinas com anticorpos alvejados para terapia |
EP2209805B1 (fr) * | 2007-10-30 | 2017-09-06 | Philogen S.p.A. | Un antigène associé à la polyarthrite rhumatoïde |
WO2010005389A1 (fr) * | 2008-07-11 | 2010-01-14 | Forskarpatent I Syd Ab | Protéines conjuguées ou fusionnées à un anticorps spécifique des protéines ldl oxydées |
JP5764127B2 (ja) | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
SG187746A1 (en) | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
PT2691417T (pt) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
RU2016135788A (ru) | 2014-02-06 | 2018-03-07 | Ф.Хоффманн-Ля Рош Аг | Иммуноконъюгаты интерлейкина 10 |
-
2013
- 2013-08-05 BR BR112015002085A patent/BR112015002085A2/pt not_active Application Discontinuation
- 2013-08-05 KR KR1020157003225A patent/KR20150038012A/ko not_active Application Discontinuation
- 2013-08-05 CN CN201380041222.1A patent/CN104540848B/zh active Active
- 2013-08-05 MA MA37793A patent/MA20150232A1/fr unknown
- 2013-08-05 SG SG11201408526SA patent/SG11201408526SA/en unknown
- 2013-08-05 JP JP2015525845A patent/JP2015530983A/ja active Pending
- 2013-08-05 MX MX2015001675A patent/MX2015001675A/es unknown
- 2013-08-05 US US13/959,051 patent/US9346872B2/en active Active
- 2013-08-05 AU AU2013301656A patent/AU2013301656A1/en not_active Abandoned
- 2013-08-05 EP EP13745407.0A patent/EP2882774B1/fr active Active
- 2013-08-05 PE PE2015000169A patent/PE20150645A1/es not_active Application Discontinuation
- 2013-08-05 EA EA201500208A patent/EA201500208A1/ru unknown
- 2013-08-05 CA CA2876285A patent/CA2876285A1/fr not_active Abandoned
- 2013-08-05 WO PCT/EP2013/066342 patent/WO2014023673A1/fr active Application Filing
- 2013-08-06 AR ARP130102781A patent/AR092050A1/es unknown
- 2013-08-07 TW TW102128385A patent/TW201418283A/zh unknown
-
2014
- 2014-12-05 CR CR20140565A patent/CR20140565A/es unknown
- 2014-12-12 CO CO14273530A patent/CO7151522A2/es unknown
- 2014-12-17 ZA ZA2014/09304A patent/ZA201409304B/en unknown
- 2014-12-31 CL CL2014003605A patent/CL2014003605A1/es unknown
-
2015
- 2015-01-19 IL IL236809A patent/IL236809A0/en unknown
- 2015-02-09 PH PH12015500284A patent/PH12015500284A1/en unknown
- 2015-10-20 HK HK15110298.1A patent/HK1209439A1/xx not_active IP Right Cessation
-
2016
- 2016-04-27 US US15/140,414 patent/US10040843B2/en active Active
-
2018
- 2018-10-05 JP JP2018190250A patent/JP6985232B2/ja active Active
-
2021
- 2021-01-26 JP JP2021009946A patent/JP2021087426A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US9346872B2 (en) | 2016-05-24 |
CL2014003605A1 (es) | 2015-04-06 |
JP2021087426A (ja) | 2021-06-10 |
IL236809A0 (en) | 2015-03-31 |
CN104540848A (zh) | 2015-04-22 |
AU2013301656A1 (en) | 2015-01-15 |
EA201500208A1 (ru) | 2015-07-30 |
CN104540848B (zh) | 2019-05-31 |
PE20150645A1 (es) | 2015-05-11 |
HK1209439A1 (en) | 2016-04-01 |
JP2015530983A (ja) | 2015-10-29 |
CA2876285A1 (fr) | 2014-02-13 |
EP2882774A1 (fr) | 2015-06-17 |
AR092050A1 (es) | 2015-03-18 |
US20160340413A1 (en) | 2016-11-24 |
CR20140565A (es) | 2015-02-12 |
JP2019033755A (ja) | 2019-03-07 |
KR20150038012A (ko) | 2015-04-08 |
ZA201409304B (en) | 2017-09-27 |
PH12015500284A1 (en) | 2015-04-27 |
MX2015001675A (es) | 2015-04-10 |
CO7151522A2 (es) | 2014-12-29 |
EP2882774B1 (fr) | 2018-10-03 |
TW201418283A (zh) | 2014-05-16 |
JP6985232B2 (ja) | 2021-12-22 |
US10040843B2 (en) | 2018-08-07 |
SG11201408526SA (en) | 2015-03-30 |
BR112015002085A2 (pt) | 2017-12-19 |
US20140044674A1 (en) | 2014-02-13 |
WO2014023673A1 (fr) | 2014-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA20150232A1 (fr) | Protéines de fusion de l'interleukine-10 et leurs utilisations | |
MA37894A1 (fr) | Protéines de fusion d'interleukine-2 et leurs utilisations | |
TR201910103T4 (tr) | Anti-fcrn antikorları. | |
MA35130B1 (fr) | Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri) | |
MA34248B1 (fr) | 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation | |
BR112013023006A8 (pt) | formulações de suspensões não aquosas de anticorpos de alta concentração e viscosidade reduzida | |
GB2513768A (en) | Complexes of cytomegalovirus proteins | |
CL2011003122A1 (es) | Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer. | |
EP4261828A3 (fr) | Procédés et procédés d'évaluation non invasive de variations génétiques | |
MA35365B1 (fr) | Pyrimidines annelées substituées et leur utilisation | |
PH12014502184A1 (en) | Anti-hla-b* 27 antibodies and uses thereof | |
EA201590247A1 (ru) | Антитела к siglec-15 | |
UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
EA201270713A1 (ru) | Белки на основе фибронектина с каркасными доменами, которые связывают ил-23 | |
MA44922B1 (fr) | Anticorps | |
EA201591791A1 (ru) | Антитела pac1 человека | |
MA38686A1 (fr) | Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés | |
EA201491784A1 (ru) | Антитела против лигандов рецептора в1 брадикинина | |
MA35935B1 (fr) | Oligonucléotides pour moduler l'expression de gènes et leurs utilisations | |
MX346475B (es) | Peptidos inmunogenicos monomericos y multimericos. | |
EA201491724A1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения | |
GB2493242A (en) | Transaction processing system | |
Abdennour et al. | Benign odontogenic tumours: epidemiological analysis of 97 cases in the Algerian population | |
WO2012084996A3 (fr) | Procédés d'identification d'oligonucléotides biologiquement actifs capables de moduler le système immunitaire | |
CN202025121U (zh) | 便捷式显微镜 |